HC Wainwright Forecasts Lower Earnings for vTv Therapeutics

vTv Therapeutics Inc. (NASDAQ:VTVT) – HC Wainwright dropped their Q3 2025 earnings per share estimates for shares of vTv Therapeutics in a note issued to investors on Wednesday, August 13th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will earn ($0.97) per share for the quarter, down from their previous estimate of ($0.93). HC Wainwright has a “Buy” rating and a $36.00 price target on the stock. HC Wainwright also issued estimates for vTv Therapeutics’ Q4 2025 earnings at ($1.03) EPS, FY2025 earnings at ($3.69) EPS, FY2026 earnings at ($3.49) EPS, FY2027 earnings at ($3.50) EPS, FY2028 earnings at ($3.45) EPS and FY2029 earnings at ($2.66) EPS.

vTv Therapeutics Trading Up 3.6%

NASDAQ:VTVT opened at $15.85 on Friday. vTv Therapeutics has a twelve month low of $12.62 and a twelve month high of $26.99. The company has a market cap of $50.56 million, a price-to-earnings ratio of -5.08 and a beta of 0.57. The stock has a fifty day simple moving average of $15.55 and a 200-day simple moving average of $17.49.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.07).

Institutional Trading of vTv Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in VTVT. Connective Capital Management LLC bought a new stake in shares of vTv Therapeutics during the first quarter worth $162,000. JPMorgan Chase & Co. bought a new stake in shares of vTv Therapeutics during the fourth quarter worth $25,000. Finally, Geode Capital Management LLC lifted its position in shares of vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 1,327 shares during the last quarter. 17.51% of the stock is currently owned by institutional investors.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.